Roivant Sciences (ROIV) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$7.5M

Revenue (quarter)

$1.4M

Revenue growth (year over year)

−33.55%

Gross profit (trailing twelve months)

$6.1M

Gross margin

81.21%

Net income (trailing twelve months)

−$414.6M

Net income (quarter)

−$290.6M

Net income growth (year over year)

−6.10%

Net margin

−5504.54%

Return on equity

−6.21%

EPS (trailing twelve months)

−$0.36

Book value per share

$5.86

P/E (trailing twelve months)

—

Price to book

5.14

Debt to assets

7.25%

Payout ratio

—

Dividend yield

—

Company profile

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

• Is Roivant Sciences (ROIV) profitable?

  No. Roivant Sciences reported a net loss of $414.6M over the trailing twelve months.

• How much revenue does Roivant Sciences (ROIV) make?

  Roivant Sciences generated $7.5M in revenue over the trailing twelve months, down 33.55% year over year.

• How do I buy stock in Roivant Sciences (ROIV)?

  ROIV trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.